<DOC>
	<DOCNO>NCT00000627</DOCNO>
	<brief_summary>To evaluate use fluconazole ( 1 ) induction therapy histoplasmosis , ( 2 ) maintenance therapy prevent relapse histoplasmosis . Histoplasmosis serious opportunistic infection patient AIDS . Fluconazole triazole antifungal agent use successfully treatment experimental histoplasmosis animal , completely evaluate patient use . It approve Food Drug Administration certain fungal infection . Nevertheless , physicians prescribe patient histoplasmosis . This pilot study examine role fluconazole treat histoplasmosis AIDS patient .</brief_summary>
	<brief_title>Pilot Study Determine Feasibility Fluconazole Induction Treatment Suppression Relapse Histoplasmosis Patients With Acquired Immunodeficiency Syndrome</brief_title>
	<detailed_description>Histoplasmosis serious opportunistic infection patient AIDS . Fluconazole triazole antifungal agent use successfully treatment experimental histoplasmosis animal , completely evaluate patient use . It approve Food Drug Administration certain fungal infection . Nevertheless , physicians prescribe patient histoplasmosis . This pilot study examine role fluconazole treat histoplasmosis AIDS patient . At least 40 patient AIDS initial episode disseminate histoplasmosis select study . Patients receive fluconazole total 12 week . Patients unable take drug orally may receive intravenously oral administration possible . Patients evaluate week 0 , 1 , 2 , 4 , 8 , 12 . Patients well without evidence clinical failure dose-limiting toxicity permit continue maintenance therapy prevent relapse reduce dose additional 12 month ; relapse reduce dose permitted receive re-induction high dose .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Histoplasmosis</mesh_term>
	<mesh_term>Fluconazole</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Corticosteroids 21 day dose great 20 mg/day prednisone ( high dos may give short duration , clinically indicate ) . Zidovudine , oral contraceptive , methadone , narcotic , acyclovir , acetaminophen , sulfonamide , trimethoprim/sulfamethoxazole , pentamidine Pneumocystis carinii pneumonia ( PCP ) PCP prophylaxis , topical antifungal , pyrimethamine , ganciclovir . Didanosine ( ddI ) , dideoxycytidine ( ddC ) , foscarnet , investigational drug consider essential patient management . Concurrent Treatment : Allowed : Transfusion . Patients must follow : HIV infection . Histoplasmosis . Appropriate consent must obtain parent legal guardian patient le 18 year age . Allowed : Hematologic and/or renal laboratory abnormality . Concurrent malignancy . Concurrent infection Mycobacteria . Patients severe manifestation histoplasmosis think risk die within one week receive 250 mg amphotericin B seven day prior enrollment reevaluate . Patients still severely ill meet eligibility criterion may enter study . Specific criterion define lifethreatening histoplasmosis include : Systolic blood pressure &lt; 90 mm Hg without cause ; arterial pO2 &lt; 60 torr without cause ; SGOT &gt; 10 x upper limit normal bilirubin &gt; 3 x upper limit normal . Any case meeting definition must review protocol chair . Prior Medication : Allowed : Amphotericin B ( 250 mg ) 7 day patient severe histoplasmosis . Risk Behavior : Allowed : Patients history highrisk behavior HIV infection ( bisexual homosexual men , intravenous drug abuser , recipient blood blood product prior May 1985 , sexual partner forego ) . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Allergy , intolerance , imidazoles azoles . Active hepatitis ( viral , drug induced , ) . Fungal infection study drug indicate ( e.g. , aspergillosis , mucormycosis ) . CNS/CSF culture positive pathogen H. capsulatum . If C. neoformans subsequently identify patient improve , patient may allow remain study permission protocol chair . Concurrent Medication : Excluded : Corticosteroid use &gt; 21 day &gt; 20 mg/day prednisone . Systemic antifungal . Prior Medication : Excluded : Amphotericin B &gt; 2.5 mg/kg current episode histoplasmosis within 7 day prior enrollment . Suppressive treatment histoplasmosis fungal infection &gt; 200 mg/day ketoconazole , fluconazole , itraconazole , 50 mg amphotericin B twice weekly . Risk Behavior : Excluded : Patients investigator feel would undependable regard adherence protocol . Patients may follow prior condition : History allergy , intolerance , imidazoles azoles .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Pilot Projects</keyword>
	<keyword>Histoplasmosis</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>Fluconazole</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Recurrence</keyword>
</DOC>